RNC Capital Management’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

RNC Capital Management’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-46,850	Closed	-$1.83M	–	157
2016 Q4	$1.83M	Buy	+46,850	New	+$1.91M	0.15%	67

Other funds holding XPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

RNC Capital Management's XPH Position: Q1 2017 in Review

RNC Capital Management sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q1 2017, closing a stake of 46,850 shares — an estimated $1.83M sold.

RNC Capital Management first reported a position in XPH in Q4 2016 and held it in 1 quarter. The position peaked at $1.83M in Q4 2016. 79 funds tracked by Wall St. Rank hold XPH as of Q1 2017.

RNC Capital Management reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q1 2017 after selling out during the quarter.
RNC Capital Management sold 46,850 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2017, an estimated $1.83M.
RNC Capital Management first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2016 and held it in 1 quarter.
RNC Capital Management's State Street SPDR S&P Pharmaceuticals ETF position peaked at $1.83M in Q4 2016.
79 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2017.

Based on RNC Capital Management's 13F filing for Q1 2017, filed 4 May 2017.